NCT03936933 2025-02-17Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast CancerEurofarma Laboratorios S.A.Phase 3 Terminated6 enrolled
NCT02751528 2025-01-13QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast CancerNantBioScience, Inc.Phase 1 Terminated3 enrolled 10 charts